Tokunaga E, Iwata H, Itoh M, Taira T, et al. Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer 2024 Oct 8. doi: 10.1007/s12282-024-01640.
PMID: 39379782